Name: OECD_SIDS / SUBSTANCE : 4-Chlorobenzaldehyde / 4-chlorobenzaldehyde /104-88-1 Fri, 16 Dec 2022, 15:26:36+0900 /Legal entity owner: National Institute of Health Sciences
Printing date: 2022-12-16T15:26:36.448+09:00

iTable of Contents
0/0 ............................................................................................................................. 1
National Institute of Health Science ..................................................................... 2
4-Chlorobenzaldehyde ......................................................................................... 3
1 General information .................................................................................. 3
1.1 Identification ................................................................................. 3
Identification ............................................................................... 3
Identification ...................................................................... 3
1.10 Assessment approach (assessment entities) ................................. 4
Assessment approach (assessment entities) ................................ 4
7 Toxicological information ......................................................................... 5
7.5 Repeated dose toxicity ................................................................... 5
7.5.1 Repeated dose toxicity: oral ................................................. 5
Repeated dose toxicity: oral.001 ........................................... 5
Repeated dose toxicity: oral.002 ......................................... 13
7.6 Genetic toxicity ............................................................................ 19
7.6.1 Genetic toxicity in vitro ...................................................... 19
Genetic toxicity in vitro.001 ................................................ 19
Genetic toxicity in vitro.002 ................................................ 23
7.8 Toxicity to reproduction ............................................................... 27
7.8.1 Toxicity to reproduction ..................................................... 27
Toxicity to reproduction.001 ............................................... 27
References ................................................................................................................ 34
Reference Substances ...................................................................................... 34
4-chlorobenzaldehyde ................................................................................ 34
Test Materials .................................................................................................. 36
4-chlorobenzaldehyde ................................................................................ 36
Literatures ....................................................................................................... 37
A reproduction/developmental toxicity screening test in rats treated orallywith 4-chlorobenzaldehyde ......................................................................... 37
In Vitro Chromosomal Aberration Test of 4-chlorobenzaldehyde on
Cultured Chinese Hamster Cells. ................................................................ 38
Reverse Mutation Test of 4-chlorobenzaldehyde on Bacteria. ....................... 39
Twenty-eight-day Repeat Dose Oral Toxicity Test of 4-Chlorobenzaldehydein Rats ...................................................................................................... 40
Legal Entities ................................................................................................... 41
National Institute of Health Sciences .......................................................... 41ii

DOSSIER:UUID: 0
Dossier UUID:
Author:Date: 2022-12-16T15:26:36.278+09:00
Remarks:

Dossier header
Dossier submission type
Name
OECD SIDS
Versioncore 7.0
Name (given by user)

Dossier subject
Dossier subject
4-Chlorobenzaldehyde / 4-chlorobenzaldehyde / 104-88-1
Public nameSubmitting legal entity
National Institute of Health Science
Dossier creation date/time
Fri, 16 Dec 2022, 15:26:36+0900
Used in category

1

LEGAL_ENTITY: National Institute of Health
Science
UUID: f51e7b54-9211-4863-90ce-fcf8a155d647
Dossier UUID:
Author:Date: 2022-11-07T16:24:02.822+09:00
Remarks:

General information
Legal entity nameNational Institute of Health Science24-Chlorobenzaldehyde
General information
Identification
Identification
SUBSTANCE: 4-Chlorobenzaldehyde

UUID: IUC5-88396134-556c-42ba-b624-833db483f5ce
Dossier UUID:
Author:Date: 2022-12-16T15:26:25.189+09:00
Remarks:
Substance name
4-Chlorobenzaldehyde
Legal entity
National Institute of Health Sciences / Kawasaki / Japan

Identification of substance
Reference substance
4-chlorobenzaldehyde / 4-chlorobenzaldehyde / 104-88-1 / 203-247-4
EC number

EC name203-247-4

EC Inventory

CAS number

CAS name

104-88-1
IUPAC name4-chlorobenzaldehyde

Role in the supply chain
Manufacturer
false
Importer
false
Only representativefalse
Downstream user
false

3

Assessment approach (assessment entities)
FIXED_RECORD: Assessment approach
UUID: 056da06e-c2c2-3441-95c5-1943551c4ece
Dossier UUID:
Author:Date: 2016-12-21T15:12:44.000+09:00
Remarks:4

Toxicological information
Repeated dose toxicity
Repeated dose toxicity: oral
ENDPOINT_STUDY_RECORD: Repeated dose toxicity: oral.001

UUID: IUC5-5c3897a9-5e38-496d-977f-60a8fb98a9cb
Dossier UUID:
Author:Date: 2022-12-16T15:21:55.215+09:00
Remarks:

Administrative data
Endpoint
short-term repeated dose toxicity: oral
Type of information
experimental study
Adequacy of study
key study
Robust study summary
false
Used for classification
false
Used for SDS
false
Reliability
1 (reliable without restriction)
Rationale for reliability incl. deficiencies
other: The study was conducted in accordance with Test Guidelines and under GLP
Cross-reference
Reason / purpose for cross-reference
reference to other study
Remarks
7.5.1 Repeated dose toxicity: oral.002

Data source
Reference
Twenty-eight-day Repeat Dose Oral Toxicity Test of 4-Chlorobenzaldehyde in Rats / MHLW / publication
Data accessdata published5

Materials and methods
Test guideline
Qualifieraccording to guideline
Guideline
other: other guideline: Guideline for 28-Day Repeated Dose Toxicity Test in Mammalian Species (Chemical Substances Control Law of Japan)
Qualifierequivalent or similar to guideline
Guideline
OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
GLP compliance
yes

Test material
Test material information
4-chlorobenzaldehyde
Specific details on test material used for the study- Name of test material (as cited in study report): p-Chlorobenzaldehyde- Analytical purity: 99.06%- Lot No.: F7049- Storage condition of test material: at a cold (temperature 1-10 ℃) and dark place, with airtight sto
pper.
- Stability under test conditions: The stability of test material was identified by analysis of the remainder.

Test animals
Speciesratcommon rodent species
Strainother: Crl:CD(SD)Sexmale/female
Details on test animals or test system and environmental conditions
TEST ANIMALS- Source: Charles River Japan, Inc.
- Age at study initiation: 5 weeks old- Weight at study initiation: male (150-177 g), female (114-131 g)- Housing: Animals were individually housed in a metallic cage with wire mesh bottoms- Diet: Solid feed (CRF-1: Oriental Yeast Co., ltd.) was given ad libitum.
- Water: Tap water was given ad libitum.
- Acclimation and quarantine period:6 days
ENVIRONMENTAL CONDITIONS- Temperature (°C): 22±3 (actual temperature: 21-25 ℃)
6

- Humidity (%): 50±20% (actual humidity: 39-56%)- Air changes (per hr): 10-15- Photoperiod (hrs dark / hrs light): 12 hr dark/12 hr light (light: 8:00~20:00)

Administration / exposure
Route of administration
oral: gavage
Vehiclecorn oilAnalytical verification of doses or concentrations
yes
Duration of treatment / exposure
28 daysFrequency of treatment
once a day
Doses / concentrations
Remarks
Doses / Concentrations:0, 8, 40, 200, 1000 mg/kg bw/day
Basis:
actual ingested
No. of animals per sex per dose
12/sex (0, 1000 mg/kg bw/day)
6/sex (8, 40, 200 mg/kg bw/day)Control animals
yes, concurrent vehicle
Details on study design- Dose selection rationale:
The dosage levels were determined based on the finding in a 14-day dose-finding study.
In a dose finding study for a 28 day study, Crl:CD(SD) rats were given 4-chlorobenzaldehyde at 0 (cornoil), 8, 40, 200 or 1000 mg/kg/day for 14 days. At 40 mg/kg/day and higher, the urine specific gravity
in males was showed a decreasing trend, at 200 mg/kg/day and higher, urine protein in males andfemales was decreased or showed a decreasing trend, and at 1000 mg/kg/day, an increase in urine
volume in males and females, and increases in AST, ALT and ALP in females were observed.
- Rationale for animal assignment (if not random): Body weight-balanced randomization- Post-exposure recovery period in satellite groups: 14 days

Examinations
Observations and examinations performed and frequency
CLINICAL OBSERVATIONS: Yes- Time schedule: every day during the administration (twice a day: am and pm) and recovery periods(twice a day: am and pm).
DETAILED CLINICAL OBSERVATIONS: Yes
The functional observational battery testing (FOB) was performed on all animals. Among themeasures in the FOB, detailed clinical observations were made before the initiation of dosing. Thereafter, detailed clinical observations were made once a week in dosing and recovery periods.
7

Sensory motor reflexes, forelimb and hindlimb grip strengths, and motor activity were measured
on week 4 of administration period (main/recovery group animals) and week 2 of recovery period(recovery group animals).
BODY WEIGHT: Yes- Time schedule for examinations: Before administration (on days 1, 7, 14, 21 and 28 of the adm
inistration period, days 7 and 14 of the recovery period) and the necropsy days after completion of
every period.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):- Food consumption: Yes. Before administration (on days 1, 7, 14, 21 and 28 of the administration p
eriod and days 7 and 14 of the recovery period)
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes- Time schedule for collection of blood: the after completion of the administration and recovery perio
ds- Anaesthetic used for blood collection: ether- Animals fasted: Yes (16-22 hours)- How many animals: all animals
CLINICAL CHEMISTRY: Yes- Time schedule for collection of blood: the day after completion of the administration and recovery
periods- Animals fasted: Yes- How many animals: all animals
URINALYSIS: Yes- Time schedule for collection of urine: on weeks 4 of the administration period and weeks 2 of therecovery period.
- Metabolism cages used for collection of urine: Yes- Animals fasted: No- How many animals: all animals
NEUROBEHAVIOURAL EXAMINATION: No
Sacrifice and pathology
GROSS PATHOLOGY: Yes
ORGAN WEIBHT: Yes [brain, pituitary gland, thyroid, adrenal, spleen, heart, liver, kidney, thymus, testis,
epididymis, prostate, seminal vescles (including coagulation gland), ovary, uterus]
HISTOPATHOLOGY: Yes [brain (cerebrum, cerebellum and medulla oblongata), pituitary gland, spinal
cord, thymus, thyroid, parathyroid, adrenal glands, spleen, heart, tongue, esophagus, stomach, liver,pancreas, duodenum, jejunum, ileum (including Peyer's patches), cecum, colon, rectal, mesentericlymph nodes, submandibular lymph nodes, trachea, lung, kidney, bladder, testis, epididymis, prostate, seminal vesicles (including coagulation glands) , ovary, uterus, vagina, eye, Harder gland, femur(including bone marrow, right) and the sciatic nerve. (see tables in the study report.)
Statistics
The homoscedasticity was analyzed by Bartlett’s test for data of grip strength, motor activity, bodyweight, body weight gain, food consumption, quantitive items of urinary findings (except for the urine
specific gravity), hematological test, biochemical test, organ weight and organ weight ratio. Whenhomogeneity was recognized, one-way analysis of variance (homogeneous data) or kruskal-wallis (non-homogenous data) was conducted. If a significant difference was detected, as the result of one-wa
y analysis of variance, Dunnett’s method was applied for comparisons between control and individual
treatment groups. And in the case of a significant difference was detected on kruskal-wallis, Mann-W
hitney’s U-test was applied for the same purpose. The trend by the group was analyzed by Kruskal-Wal
lis for general appearance, detailed clinical observation, qualitative items of urinary findings, and urine
specific gravity. If a significant difference was detected as the result of kruskal-wallis, Mann-Whitn
ey’s U-test as applied for comparisons between control and individual treatment groups.

Results and discussion
8

Results of examinations
Clinical signs
effects observed, treatment-related
Description (incidence and severity)(see Details on results)
Mortality
mortality observed, treatment-related
Description (incidence)(see Details on results)
Body weight and weight changes
effects observed, treatment-related
Description (incidence and severity)(see Details on results)
Food consumption and compound intake (if feeding study)
effects observed, treatment-related
Description (incidence and severity)(see Details on results)
Haematological findings
effects observed, treatment-related
Description (incidence and severity)(see Details on results)
Clinical biochemistry findings
effects observed, treatment-related
Description (incidence and severity)(see Details on results)
Urinalysis findings
effects observed, treatment-related
Description (incidence and severity)(see Details on results)
Behaviour (functional findings)
effects observed, treatment-related
Description (incidence and severity)(see Details on results)
Organ weight findings including organ / body weight ratios
effects observed, treatment-related
Description (incidence and severity)(see Details on results)
Gross pathological findings
effects observed, treatment-related
Description (incidence and severity)(see Details on results)
9Histopathological findings: non-neoplastic
effects observed, treatment-related
Description (incidence and severity)(see Details on results)
Details on results
CLINICAL SIGNS AND MORTALITY
Transient salivation and tremors were observed in both sexes at 1,000 mg/kg bw/day. Soiled fur wasobserved in females at 1,000 mg/kg bw/day.
BODY WEIGHT AND WEIGHT GAIN
At 1,000 mg/kg bw/day, a decrease in body weight gain was observed in males.
FOOD CONSUMPTION
At 1,000 mg/kg bw/day, an increase in food consumption was observed in females.
HAEMATOLOGY
At 1,000 mg/kg bw/day, a decrease in platelet was observed in males.
CLINICAL CHEMISTRY
At 1,000 mg/kg bw/day, increases in serum aspartate aminotransferase and alanine aminotransfe
rase levels were observed in both sexes, whereas decreases in total protein and β-globulin fraction
were observed in males, and increases in alkaline phosphatase and triglyceride levels were observedin females.
URINALYSIS
At 1,000 mg/kg bw/day, an increase in urine volume in males and females and decreases in urine pH
and protein and specific gravity levels in males were observed.
NEUROBEHAVIOUR
At 1,000 mg/kg bw/day, a decrease in grip strength of forearms was observed in males, and a decrea
se in the locomotor activity was observed in females.
ORGAN WEIGHTS
Increased liver weight and decreased ovary and heart weights were observed at 1,000 mg/kg bw/day
in females.
GROSS PATHOLOGY
At 1,000 mg/kg bw/day, atrophy of lateral vastus muscle in one male and multifocal mucosal black
patch in glandular stomach in one female were observed.
HISTOPATHOLOGY: NON-NEOPLASTIC
Histopathological examinations revealed hyperostosis metaphysis of the femur in females at 200
mg/kg bw/day. Furthermore, at 1,000 mg/kg bw/day, hyperkeratosis of the mucosal epithelium inthe forestomach, grade enhancement of regeneration of the tubular epithelium, dilatation of the rena
l tubules in the cortex, and cyst-like extension of the collecting duct in the kidney, and hyperostosis
metaphysis of the femur were observed in both sexes. Additionally in males at 1,000 mg/kg bw/day, degeneration of nerve fibers in the sciatic nerve and atrophy of muscle fibers in the skeletal muscle
were observed. And in females at 1,000 mg/kg bw/day, squamous cell hyperplasia of the boundary edge in the stomach was observed. These changes tended to resolve after the recovery period.

Effect levels
Key result
false
10

Dose descriptor
NOAEL
Effect level200

mg/kg bw/day (actual dose received)

Based ontest mat.
Sex
male
Basis for effect level
other: see 'Remark'At 1,000 mg/kg bw/day in males: Transient salivation and tremors were observed, and decreases
in body weight gain and grip strength of forearms were observed, increases in serum aspartate
aminotransferase and alanine aminotransferase levels, decreases in total protein and β-globulin
fraction were observed, and hyperkeratosis of the mucosal epithelium in the forestomach, grade enhancement of regeneration of the tubular epithelium, dilatation of the renal tubules in the cortex,
and cyst-like extension of the collecting duct in the kidney, and hyperostosis metaphysis of the fe
mur were observed. Additionally, degeneration of nerve fibers in the sciatic nerve and atrophy of mu
scle fibers in the skeletal muscle were observed.
Key result
false
Dose descriptor
NOAEL
Effect level40

mg/kg bw/day (actual dose received)

Based ontest mat.
Sex
femaleBasis for effect level
other: Histopathological examinations revealed hyperostosis metaphysis of the femur in females at
200 mg/kg bw/day.

Target system / organ toxicity
Key result
false
Critical effects observed
not specified

Any other information on results incl. tables

11

Figures and Tables (in English) are available in the following full report of the study.
http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF104 -88 -1b.pdf

Applicant's summary and conclusion
Executive summary
In a 28-day repeated-dose toxicity test performed according to OECD TG 407, male and female rats
(6 animals/sex/dose) were administered 4-chlorobenzaldehyde at 0, 8, 40, 200, and 1,000 mg/kg bw/
day. In addition, both sexes (6 animals/sex/dose) were administered 0 and 1,000 mg/kg bw/day ofthis substance for 28 days and examined after a 14-day recovery period. At 1,000 mg/kg bw/day,transient salivation and tremors were observed in both sexes, decreases in body weight gain and grip
strength of forearms were observed in males, and a decrease in the locomotor activity was observedin females. At this dose, increases in serum aspartate aminotransferase and alanine aminotransferase
levels were observed in both sexes, whereas decreases in total protein and β-globulin fraction wereobserved in males, and increases in alkaline phosphatase and triglyceride levels were observed infemales. Increased liver weight and decreased ovary weight were also observed at 1,000 mg/kg bw/day
in females. Histopathological examinations revealed hyperostosis metaphysis of the femur in females
at 200 mg/kg bw/day. Furthermore, at 1,000 mg/kg bw/day, hyperkeratosis of the mucosal epitheliumin the forestomach, grade enhancement of regeneration of the tubular epithelium, dilatation of the renal
tubules in the cortex, and cyst-like extension of the collecting duct in the kidney, and hyperostosis
metaphysis of the femur were observed in both sexes. Additionally in males at 1,000 mg/kg bw/day,degeneration of nerve fibers in the sciatic nerve and atrophy of muscle fibers in the skeletal muscle wereobserved. And in females at 1,000 mg/kg bw/day, squamous cell hyperplasia of the boundary edge inthe stomach was observed. These changes tended to resolve after the recovery period. On the basis ofthese effects, NOAELs for repeated-dose toxicity were determined to be 200 mg/kg bw/day and 40 mg/
kg bw/day in male and female rats, respectively.

12

ENDPOINT_STUDY_RECORD: Repeated dose toxicity: oral.002

UUID: IUC5-520d8d8b-7f48-4e05-b483-817f6ebe17ce
Dossier UUID:
Author:Date: 2022-12-16T15:23:28.532+09:00
Remarks:

Administrative data
Endpoint
repeated dose toxicity: oral combined repeated dose and reproduction / developmental screening
deactivated phrase
Type of information
experimental study
Adequacy of study
key study
Robust study summary
false
Used for classification
false
Used for SDS
false
Reliability
1 (reliable without restriction)
Rationale for reliability incl. deficiencies
other: GLP guideline study
Cross-reference
Reason / purpose for cross-reference
reference to same study
Remarks
7.8.1 Toxicity to reproduction.001

Reason / purpose for cross-reference
reference to other study
Remarks
7.5.1 Repeated dose toxicity: oral.001

Data source
Reference
A reproduction/developmental toxicity screening test in rats treated orally with 4-chlorobenzaldehyd /MHLW, Japan / study report13Data accessdata published

Materials and methods
Test guideline
Qualifieraccording to guideline
Guideline
other: OECD TG 421: Reproduction/developmental toxicity screening test
Deviationsno
GLP compliance
yes
Limit test
no

Test material
Test material information
4-chlorobenzaldehyde
Specific details on test material used for the study- Name of test material (as cited in study report): 4-chlorobenzaldehyde- Purity: 99.8%- Lot/batch No.: QJ5LK- Stability under test conditions: Stable- Storage condition of test material: a cool (2-8 °C) and dark place (in a refrigerator), with an airtightstopper- Dosing solution storage condition: under room temperature (19-23 °C) in a brown glass bottle- Other: The dosing solution was used within 7 days of preparation.

Test animals
Speciesratcommon rodent species
Strainother: Crl: CD(SD)Sexmale/female
Details on test animals or test system and environmental conditions
TEST ANIMALS- Source: Charles River Laboratories Japan, Inc. Tsukuba- Age at study initiation: 10 weeks- Weight at study initiation: Males: 389-449 g; Females: 234-271 g- Housing: Steel wire-mesh cage (250 mm x 350 mm x 200 mm )- Diet: ad libitum- Water: ad libitum14

- Acclimation period: 14 days
ENVIRONMENTAL CONDITIONS- Temperature (°C): 20-25- Humidity (%): 41-69- Air changes: 10-15 times / hr
- Photoperiod: 12 hrs dark / 12 hrs light (07:00-19:00)

Administration / exposure
Route of administration
oral: gavage
Vehiclecorn oilAnalytical verification of doses or concentrations
yes
Duration of treatment / exposure(P) Males: 42 days including 14 days pre-mating and mating periods, and thereafter 14 days (P) Femal
es: 42-45 days including 14 days pre-mating, mating and gestation periods, and the days until day 4 oflactation
Frequency of treatment
Once/day, 7days/week
Doses / concentrations
Remarks
Doses / Concentrations:
0 (vehicle), 40, 200, and 1000 mg/kg bw/day
Basis:
actual ingested
No. of animals per sex per dose
12 animals/sex/doseControl animals
yes, concurrent vehicle
Details on study design- Dose selection rationale: Doses in this test were set based on the results of the following study: 28day repeated dose oral toxicity test (doses: 0, 8, 40, 200, and 1000 mg/kg bw/day). At 1,000 mg/kg
bw/day, transient salivation and tremors were observed in both sexes, decreases in body weight gain
and grip strength of forearms were observed in males, and a decrease in the locomotor activity wasobserved in females. At this dose, increases in serum aspartate aminotransferase and alanine aminotransferase levels were observed in both sexes, whereas decreases in total protein and β-globulin fr
action were observed in males, and increases in alkaline phosphatase and triglyceride levels were ob
served in females. Increased liver weight and decreased ovary weight were also observed at 1,000
mg/kg bw/day in females. Histopathological examinations revealed hyperostosis metaphysis of t
he femur in females at 200 mg/kg bw/day. Furthermore, at 1,000 mg/kg bw/day, hyperkeratosis of
the mucosal epithelium in the forestomach, grade enhancement of regeneration of the tubular epi
thelium, dilatation of the renal tubules in the cortex, and cyst-like extension of the collecting duct inthe kidney, and hyperostosis metaphysis of the femur were observed in both sexes. Additionally inmales at 1,000 mg/kg bw/day, degeneration of nerve fibers in the sciatic nerve and atrophy of muscle
fibers in the skeletal muscle were observed. And in females at 1,000 mg/kg bw/day, squamous cel
15l hyperplasia of the boundary edge in the stomach was observed. These changes tended to resolve
after the recovery period.
- Rationale for animal assignment (if not random): Body weight-balanced randomization

Examinations
Observations and examinations performed and frequency
CAGE SIDE OBSERVATIONS: Yes- Time schedule:
Males and females: 3 times/day
BODY WEIGHT: Yes- Time schedule for examinations:
Males: Days 1, 4, 8, 11, 15, 22, 25, 29, 32, 36, 39, 42, and the day of necropsy
Females: Twice a week during the precopulation period (days 1, 4, 8, 11, and 15); gestation days 0, 4,
7, 11, 14, 17, and 20; lactation days 0 and 4; and the day of necropsy
FOOD CONSUMPTION: Yes
Males: Days 1, 4, 8, 11, 15, 32, 36, 39, and 42 in dosing period
Females: Days 1, 4, 8, 11, and 15; gestation days 1, 4, 7, 11, 14, 17, and 20; lactation days 2 and 4
HAEMATOLOGY: No
CLINICAL CHEMISTRY: No
URINALYSIS: No
Sacrifice and pathology
GROSS PATHOLOGY: Yes (see tables)
HISTOPATHOLOGY: Yes (epididymis, prostate, seminal vesicle, testis, ovary, uterus, vagina, and grossabnormal sites)
Other examinations
Organ weight: Testes and epididymides
Statistics
The data were analyzed for homogeneity of variance by the Bartlett test. If variances were
homogeneous, data was analyzed by the Dunnett test, whereas heterogeneous data was analyzed by
the steel test (p<0.05, two-sided).

Results and discussion
Results of examinations
Clinical signs
effects observed, treatment-related
Description (incidence and severity)
Nine males and seven females died with tremors and decreased locomotor activity at 1,000 mg/kg
bw/day by day 9 of administration.
16

Mortality
mortality observed, treatment-related
Description (incidence)Nine males and seven females died with tremors and decreased locomotor activity at 1,000 mg/kg
bw/day by day 9 of administration.
Body weight and weight changes
effects observed, treatment-related
Description (incidence and severity)
Low value of body weight was observed in both sexes at 1,000 mg/kg bw/day.
Food consumption and compound intake (if feeding study)
effects observed, treatment-related
Description (incidence and severity)
Low value of food consumption was observed in both sexes at 1,000 mg/kg bw/day.
Food efficiency
not examined
Water consumption and compound intake (if drinking water study)
not examined
Ophthalmological findings
not examined
Haematological findings
not examined
Clinical biochemistry findings
not examined
Urinalysis findings
not examined
Behaviour (functional findings)
not examined
Organ weight findings including organ / body weight ratios
no effects observed
Gross pathological findings
effects observed, treatment-related
Description (incidence and severity)
see tables.
Histopathological findings: non-neoplastic
effects observed, treatment-related
Description (incidence and severity)
see tables.
Histopathological findings: neoplastic
not examined

Effect levels
17Key result
false
Dose descriptor
NOAEL
Effect level200

mg/kg bw/day (actual dose received)

Based ontest mat.
Sexmale/female
Basis for effect level
other: Nine males and seven females died with tremors and decreased locomotor activity at 1,000 m
g/kg bw/day by day 9 of administration.

Target system / organ toxicity
Key result
false
Critical effects observed
not specified

Any other information on results incl. tables
Figures and Tables (in English) are available in the following full report of the study.
http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF104 -88 -1c.pdf

Applicant's summary and conclusion
Conclusions
In this study, NOAEL for repeated-dose toxicity was determined to be 200 mg/kg bw/day in male andfemale rats.
Executive summary
A reproduction/developmental toxicity screening test was performed according to OECD TG 421. Maleand female rats (12 animals/sex/dose) were administered 4-chlorobenzaldehyde at 0, 40, 200, and
1,000 mg/kg bw/day. Males were dosed for 42 days, including a 14 day pre-mating and mating periods.
Females were dosed for 42–45 days, including a 14-day pre-mating, mating, and gestation periods
and the time until day 4 of lactation. Nine males and seven females died with tremors and decreased
locomotor activity at 1,000 mg/kg bw/day by day 9 of administration. In this study, NOAEL for repeateddose toxicity was determined to be 200 mg/kg bw/day in male and female rats.

18

Genetic toxicity
Genetic toxicity in vitro
ENDPOINT_STUDY_RECORD: Genetic toxicity in vitro.001

UUID: IUC5-6657ee02-5cbb-4ca8-9b60-b74d46361195
Dossier UUID:
Author:Date: 2022-12-16T15:24:28.172+09:00
Remarks:

Administrative data
Endpoint
in vitro gene mutation study in bacteria Type of genotoxicity: gene mutation
Type of information
experimental study
Adequacy of study
key study
Robust study summary
false
Used for classification
false
Used for SDS
false
Reliability
1 (reliable without restriction)
Rationale for reliability incl. deficiencies
other: OECD Test Guideline study under GLP condition

Data source
Reference
Reverse Mutation Test of 4-chlorobenzaldehyde on Bacteria. / MHLW, Japan / study report
Data accessdata published

Materials and methods
Test guideline
Qualifieraccording to guideline
19Guideline
JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
Qualifieraccording to guideline
Guideline
OECD Guideline 471 (Bacterial Reverse Mutation Assay)
in vitro gene mutation study in bacteria
GLP compliance
yesType of assay
bacterial reverse mutation assay
in vitro gene mutation study in bacteria

Test material
Test material information
4-chlorobenzaldehyde
Specific details on test material used for the study- Name of test material (as cited in study report): p-chlorobenzaldehyde- Purity: 99.06%- Lot/batch No.: F7049- Storage condition of test material: in a hermetically sealed and light-resistant container at cool (2-9℃) place- Stability under test conditions: The stability of test material was identified by analysis of the remainder.

MethodSpecies / strain
Species / strain / cell typeS. typhimurium TA 1535, TA 1537, TA 98 and TA 100
bacteria
Species / strain / cell type
E. coli WP2 uvr A
bacteria
Metabolic activation
with and without
Metabolic activation system
rat liver, induced by phenobarbital and 5,6-benzoflavone
Test concentrations with justification for top dose
-S9 mix and + S9 mix: 15.6, 31.3, 62.5, 125, 250, 500 μg/plate (all strains)
Vehicle / solvent- Vehicle(s)/solvent(s) used: DMSO
20

Controls
Untreated negative controlsnoNegative solvent / vehicle controls
yes
True negative controls
other: tests without all strains, and with vehicle, S9 mix or the highest dose
Positive controls
yes
Positive control substanceother: -S9 mix: 2-(2-Furyl)-3-(5-nitro-2-furyl) acrylamide (AF2:TA 100, TA98 & WP2 uvrA), sodium
azide (SA:TA1535) and 9-aminoacridine hydrochloride (9AA:TA1537). +S9 mix: 2-aminoanthracene(2AA:all strains).
Details on test system and experimental conditions
RANGE-FINDING/SCREENING STUDIES:
Concentration: 20-5000 μg/plate
Cytotoxic conc.: Yes, >500 μg/plate
Precipitate: No.
METHOD OF APPLICATION: Preincubation
DURATION- Preincubation period: 20 min at 37 ℃
- Exposure duration:48-49 hrs
NUMBER OF PLATES: 3
NUMBER OF REPLICATIONS: 2
DETERMINATION OF CYTOTOXICITY- Method: other: growth inhibition
Evaluation criteria
In any strain(s) tested with or without S9 mix, when the mean number of revertant colonies per plateincreased twice more than that of the negative control and when the increase was shown to be dose-r
elated and reproducible, the chemical was judged mutagenic.
Statistics
No.

Results and discussion
Test results
Key result
false
Species / strain
S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
bacteria
Metabolic activation
with and without
Genotoxicity
negative21

Cytotoxicity / choice of top concentrations
cytotoxicity -S9 mix: 500 μg/plate, +S9 mix: >250 μg/plate
Vehicle controls validity
valid
Untreated negative controls validity
valid
Positive controls validity
valid
Key result
false
Species / strain
E. coli WP2 uvr A
bacteria
Metabolic activation
with and without
Genotoxicity
negative
Cytotoxicity / choice of top concentrations
cytotoxicity -S9 mix: 500 μg/plate, +S9 mix: >250 μg/plate
Vehicle controls validity
valid
Untreated negative controls validity
valid
Positive controls validity
valid
Additional information on results
Contamination with any other bacterias was not found.
Remarks on result
other: all strains/cell types tested Migrated from field 'Test system'.

Any other information on results incl. tables
Field content is not in a valid XML format and thus ignored!

Applicant's summary and conclusion
Conclusions
Interpretation of results (migrated information):negative
Executive summary
In a bacterial reverse mutation assay using S. typhimurium TA100, TA1535, TA98, and TA1537 and E.
coli WP2uvrA (OECD TG 471), 4-chlorobenzaldehyde was negative with or without metabolic activation.

22

ENDPOINT_STUDY_RECORD: Genetic toxicity in vitro.002

UUID: IUC5-df6301ac-67fc-4017-b622-6ee93cc170fe
Dossier UUID:
Author:Date: 2022-12-16T15:25:06.576+09:00
Remarks:

Administrative data
Endpoint
in vitro cytogenicity / chromosome aberration study in mammalian cells Type of genotoxicity:
chromosome aberration
Type of information
experimental study
Adequacy of study
key study
Robust study summary
false
Used for classification
false
Used for SDS
false
Reliability
1 (reliable without restriction)
Rationale for reliability incl. deficiencies
other: OECD Test Guideline study under GLP condition

Data source
Reference
In Vitro Chromosomal Aberration Test of 4-chlorobenzaldehyde on Cultured Chinese Hamster Cells. /MHLW, Japan / study report
Data accessdata published

Materials and methods
Test guideline
Qualifieraccording to guideline
Guideline
OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)in vitro cytogenicity / chromosome aberration study in mammalian cells
23Deviations
no
Qualifieraccording to guideline
Guideline
JAPAN: Guidelines for Screening Mutagenicity Testing Of Chemicals
Deviationsno
GLP compliance
yesType of assay
in vitro mammalian chromosome aberration test
chromosome aberration

Test material
Test material information
4-chlorobenzaldehyde
Specific details on test material used for the study- Name of test material (as cited in study report): p-chlorobenzaldehyde- Analytical purity: 99.06%- Lot/batch No.: F7049- Storage condition of test material: in a hermetically sealed and light-resistant container at cool (2-9℃) place- Stability under test conditions: The stability of test material was identified by analysis of the remainder.

MethodTarget gene
Chromosome
Species / strain
Species / strain / cell typeother: Chinese hamster lung(CHL/IU) cells
Metabolic activation
with and without
Metabolic activation system
rat liver, induced by phenobarbital and 5,6-benzoflavone
Test concentrations with justification for top dose
-S9 mix (short-term treatment): 0, 21.9, 43.8, 87.5, 175, 263, 350 ug/mL-S9 mix (short-term treatment, confirmatory test 1): 0, 43.8, 87.5, 175, 219, 263, 307, 350 ug/mL-S9 mix (short-term treatment, confirmatory test 2): 0, 87.5, 175, 219, 263, 307, 350 ug/mL+S9 mix (short-term treatment): 0, 87.5, 175, 350, 700, 1050, 1400 ug/mL+S9 mix (short-term treatment, confirmatory test 1): 0, 87.5, 175, 350, 467, 583, 700 ug/mL-S9 mix (continuous treatment, 24 h): 0, 5.47, 10.9, 21.9, 43.8, 87.5, 131, 175 ug/mL-S9 mix (continuous treatment, 24 h, confirmatory test 1): 0, 21.9, 43.8, 87.5, 109, 131 ug/mL
24

-S9 mix (continuous treatment, 24 h, confirmatory test 2): 0, 21.9, 43.8, 65.7, 87.5, 109, 131 ug/mL
Vehicle / solvent- Vehicle(s)/solvent(s) used: DMSO
Controls
Untreated negative controlsnoNegative solvent / vehicle controls
yes
True negative controlsnoPositive controls
yes
Positive control substancebenzo(a)pyrene
cyclophosphamide
mitomycin C
Remarks
mitomycin C (without S9 mix), benzo[a]pyrene or 3,4-benzopyrene (with S9 mix)
Details on test system and experimental conditions
METHOD OF APPLICATION: Exposure duration: [continuous treatment]: 24 hrs [short-term treatment]:6 hrs + 18 hr
SPINDLE INHIBITOR: Colcemid
NUMBER OF REPLICATIONS: 2-3
NUMBER OF CELLS EVALUATED: 200 cells / dose
DETERMINATION OF CYTOTOXICITY- Method: relative total growth
Evaluation criteria
For the evaluation of the frequencies of structural aberrations and of polyploidy induced, the following
criteria were employed.
Appearance incidence of cells with chromosomal aberrations: Negative (-): < 5%; equivocal (±): 5-10%;
positive (+): > 10%.
Finally, the substance is positive when the incidence is considered to be dose-related and repro
ducible.
Statistics
not used.

Results and discussion
Test results
Key result
false
Species / strainother: Chinese hamster lung (CHL/IU) cells
Metabolic activation
with25

Genotoxicity
positive D20: 0.65 mg/mL (main test), 0.57 mg/mL (confirmatory test)
Cytotoxicity / choice of top concentrations
cytotoxicity >50% cell growth inhibition: >700 ug/mL (short, main), >700 ug/mL (short, confirmatory
test)
Vehicle controls validity
valid
Untreated negative controls validity
not examined
Positive controls validity
valid
Key result
false
Species / strainother: Chinese hamster lung (CHL/IU) cells
Metabolic activation
without
Genotoxicity
positive D20: 0.24 mg/mL (main test), 0.26 mg/mL (confirmatory-2)
Cytotoxicity / choice of top concentrations
cytotoxicity >50% cell growth inhibition: >350 ug/mL (short, main), >131 ug/mL (24h, main), >263
ug/mL (short, confirmatory-1), >131 ug/mL (24h, confirmatory-1), >307 ug/mL (short, confirmatory-2), >109 ug/mL (24h, confirmatory-2)
Vehicle controls validity
valid
Untreated negative controls validity
not examined
Positive controls validityvalid

Any other information on results incl. tables

Figures and Tables (in English) are available in the following full report of the study.
http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF104 -88 -1f.pdf

Applicant's summary and conclusion
Executive summary
An in vitro chromosomal aberration test using CHL/IU cells (OECD TG 473) showed positive.

26

Toxicity to reproduction
Toxicity to reproduction
ENDPOINT_STUDY_RECORD: Toxicity to reproduction.001

UUID: IUC5-24c0bbaa-17a7-4f00-b6e7-24491d5a34b4
Dossier UUID:
Author:Date: 2022-12-16T15:26:11.340+09:00
Remarks:

Administrative data
Endpoint
screening for reproductive / developmental toxicity based on test type (migrated information)
Type of information
experimental study
Adequacy of study
key study
Robust study summary
false
Used for classification
false
Used for SDS
false
Reliability
1 (reliable without restriction)
Rationale for reliability incl. deficiencies
other: OECD Test Guideline study under GLP condition
Cross-reference
Reason / purpose for cross-reference
reference to same study
Remarks
7.5.1 Repeated dose toxicity: oral.002

Data source
Reference
A reproduction/developmental toxicity screening test in rats treated orally with 4-chlorobenzaldehyd /MHLW, Japan / study report
Data accessdata published27

Materials and methods
Test guideline
Qualifieraccording to guideline
Guideline
other: OECD TG 421: Reproduction/developmental toxicity screening test
Deviationsno
GLP compliance
yes
Limit test
no

Test material
Test material information
4-chlorobenzaldehyde
Specific details on test material used for the study- Name of test material (as cited in study report): 4-chlorobenzaldehyde- Purity: 99.8%- Lot/batch No.: QJ5LK- Stability under test conditions: Stable- Storage condition of test material: a cool (2-8 °C) and dark place (in a refrigerator), with an airtightstopper- Dosing solution storage condition: under room temperature (19-23 °C) in a brown glass bottle- Other: The dosing solution was used within 7 days of preparation.

Test animals
Speciesrat
Strainother: Crl:CD(SD)Sexmale/female
Details on test animals or test system and environmental conditions
TEST ANIMALS- Source: Charles River Laboratories Japan, Inc. Tsukuba- Age at study initiation: 10 weeks- Weight at study initiation: Males: 389-449 g; Females: 234-271 g- Housing: Steel wire-mesh cage (250 mm x 350 mm x 200 mm )- Diet: ad libitum- Water: ad libitum- Acclimation period: 14 days
ENVIRONMENTAL CONDITIONS- Temperature (°C): 20-25- Humidity (%): 41-69
28

- Air changes: 10-15 times / hr
- Photoperiod: 12 hrs dark / 12 hrs light (07:00-19:00)

Administration / exposure
Route of administration
oral: gavage
Vehiclecorn oil
Details on mating procedure- M/F ratio per cage:1:1- Length of cohabitation:up to 14 days
- Proof of pregnancy: [vaginal plug / sperm in vaginal smear] referred to as [day 0] of pregnancy

Analytical verification of doses or concentrations
yes
Duration of treatment / exposure(P) Males: 42 days including 14 days pre-mating and mating periods, and thereafter 14 days (P) Femal
es: 42-45 days including 14 days pre-mating, mating and gestation periods, and the days until day 4 oflactation
Frequency of treatment
Once/day, 7days/week
Doses / concentrations
Remarks
Doses / Concentrations:
0 (vehicle), 40, 200, and 1000 mg/kg bw/day
Basis:
actual ingested
No. of animals per sex per dose
12 animals/sex/doseControl animals
yes, concurrent vehicle

Examinations
Parental animals: Observations and examinations
CAGE SIDE OBSERVATIONS: Yes- Time schedule:
Males and females: 3 times/day
BODY WEIGHT: Yes- Time schedule for examinations:
Males: Days 1, 4, 8, 11, 15, 22, 25, 29, 32, 36, 39, 42, and the day of necropsy
Females: Twice a week during the precopulation period (days 1, 4, 8, 11, and 15); gestation days 0, 4,
7, 11, 14, 17, and 20; lactation days 0 and 4; and the day of necropsy
29

FOOD CONSUMPTION: Yes
Males: Days 1, 4, 8, 11, 15, 32, 36, 39, and 42 in dosing period
Females: Days 1, 4, 8, 11, and 15; gestation days 1, 4, 7, 11, 14, 17, and 20; lactation days 2 and 4
OTHER: Females: Numbers of corpus luteum and implantation site on the day of necropsy
Oestrous cyclicity (parental animals)
Vaginal smears were collected from all females in the main groups and microscopically examined
every day from the day after the start of administration until the day copulation was confirmed.
During the pre-mating administration period, vaginal smear pictures were classified as proestrus,
estrus, metestrus or diestrus and examined for the frequency of estrus and interval between estruses(estrous cycle). During the mating period, vaginal smears were examined for the presence of sperm.
Sperm parameters (parental animals)
Parameters examined in P male parental generations: testes weight, epididymides weight
Litter observations
PARAMETERS EXAMINED:The following parameters were examined in F1 offspring [number and sexof pups, stillbirths, live births, postnatal mortality, presence of gross anomalies, and weight].
GROSS EXAMINATION OF DEAD PUPS: Yes, for external and internal abnormalities.
Postmortem examinations (parental animals)
SACRIFICE:
Male animals: Rats were euthanized by exsanguination under ether anesthesia on the day after the last administration.
Maternal animals: Rats were euthanized by exsanguination under ether anesthesia on day 4 of lactati
on.
GROSS PATHOLOGY: Yes (see tables)
HISTOPATHOLOGY: Yes (epididymis, prostate, seminal vesicle, testis, ovary, uterus, vagina, and grossabnormal sites)
ORGAN WEIGHTS, Yes: Testes and epididymis
Postmortem examinations (offspring)
GROSS NECROPSY- Gross necropsy consisted of external and internal examinations including the cervical, thoracic, andabdominal viscera.
Statistics
The data were analyzed for homogeneity of variance by the Bartlett test. If variances were
homogeneous, data was analyzed by the Dunnett test, whereas heterogeneous data was analyzed by
the Steel test (p<0.05, two-sided).
Especially,
Implantation index, Stillborn index, Liveborn index, External abnormalities, Viability index: the Steel test
(p<0.05 and <0.01, two-sided)
Copulation index, Fertility index, Insemination index, Delivery index: Fisher's exact test (p<0.05 and <0.
01, two-sided)
Reproductive indices
Each parameter was determined by the following equations:
Copulation index (%) = (No. of copulated animals/No. of co-housed animals) × 100
Fertility index (%) = (No. of pregnant females/No. of copulated females) × 100
Insemination index (%) = (No. of pregnant females/No. of copulated males) × 100
Duration of gestation (days) = day 0 of lactation – day 0 of gestation
Delivery index (%) = (No. of females delivered liveborn pups/No. of pregnant females) × 100
30

Implantation index (%) = (No. of implantation sites/No. of corpora lutea) × 100
Stillborn index (%) = (No. of stillborn pups/Total No. of pups born) × 100
Liveborn index (%) = (No. of liveborn pups/Total No. of pups born) × 100
External abnormalities (%) = (No. of pups with external abnormalities/No. of liveborn pups) × 100
Sex ratio = No. of liveborn male pups/(No. of liveborn male pups + No. of liveborn female pups)

Offspring viability indices
Viability index (%) = (No. of surviving pus on day 4 after birth/No. of liveborn pups on day 0 after birth)
× 100

Results and discussion
Results: P0 (first parental generation)
General toxicity (P0)
Clinical signs
effects observed, treatment-related
Description (incidence and severity)see 7.5.1 Repeated dose toxicity: oral.002
Body weight and weight changes
effects observed, treatment-related
Description (incidence and severity)see 7.5.1 Repeated dose toxicity: oral.002
Food consumption and compound intake (if feeding study)
effects observed, treatment-related
Description (incidence and severity)see 7.5.1 Repeated dose toxicity: oral.002
Organ weight findings including organ / body weight ratios
no effects observed
Description (incidence and severity)
on reproductive organs
Gross pathological findings
no effects observed
Description (incidence and severity)
on reproductive organs
Histopathological findings: non-neoplastic
no effects observed
Description (incidence and severity)
on reproductive organs

Reproductive function / performance (P0)31

Reproductive function: oestrous cycle
no effects observed
Reproductive function: sperm measures
not examined
Reproductive performanceno effects observed
Description (incidence and severity)
on reproductive organs

Effect levels (P0)
Key result
false
Dose descriptor
NOAEL
Effect level200

mg/kg bw/day (actual dose received)

Sexmale/female
Basis for effect level
other: Nine males and seven females died with tremors and decreased locomotor activity at 1,000 m
g/kg bw/day by day 9 of administration.

Results: F1 generation
General toxicity (F1)Clinical signs
no effects observed
Mortality / viability
no mortality observed
Body weight and weight changes
no effects observed
Sexual maturation
not examined
Organ weight findings including organ / body weight ratios
not examined
Gross pathological findings
no effects observed
Histopathological findings
not examined

Effect levels (F1)32

Key result
false
Dose descriptor
NOAEL
Generation
F1
Effect level200

mg/kg bw/day (actual dose received)

Sexmale/female
Basis for effect level
other: Administration of 4-chlorobenzaldehyde at 1,000 mg/kg bw/day was halted because of the frequent deaths in male and female rats.

Overall reproductive toxicity
Key result
false
Reproductive effects observed
not specified

Any other information on results incl. tables
Figures and Tables (in English) are available in the following full report of the study.
http://dra4.nihs.go.jp/mhlw_data/home/pdf/PDF104 -88 -1c.pdf

Applicant's summary and conclusion
Conclusions
NOAEL for the rat reproductive/developmental toxicity of 4-chlorobenzaldehyde was determined to be
200 mg/kg bw/day.

Executive summary
In the reproduction/developmental toxicity screening test (0, 40, 200, and 1,000 mg/kg bw/day)(OECD TG 421), administration of 4-chlorobenzaldehyde at 1,000 mg/kg bw/day was halted becauseof the frequent deaths in male and female rats. No effects of this substance on reproductive anddevelopmental parameters were observed at 200 mg/kg bw/day. NOAEL for the rat reproductive/
developmental toxicity of 4-chlorobenzaldehyde was determined to be 200 mg/kg bw/day.

33

References
Reference Substances
REFERENCE_SUBSTANCE: 4-chlorobenzaldehyde
UUID: ECB5-0baf6234-8c2b-4e38-9592-5f8028824cc8
Dossier UUID:
Author:Date: 2016-12-21T15:12:20.000+09:00
Remarks:
Reference substance name4-chlorobenzaldehyde
IUPAC name4-chlorobenzaldehyde

Inventory
Inventory number
Inventory name4-chlorobenzaldehyde
Inventory
EC Inventory
Inventory number
203-247-4
CAS number
104-88-1
Molecular formula
C7H5ClO
Description
CAS number
104-88-1

Synonyms
Synonyms
Identity
4-chlorobenzaldehyde
Identity
Benzaldehyde, 4-chloro-

Molecular and structural information
34

Molecular formula
C7H5ClO
Molecular weight140.567
SMILES notation
Clc1ccc(C=O)cc1
InChl
InChI=1/C7H5ClO/c8-7-3-1-6(5-9)2-4-7/h1-5H
Structural formula

Related substancesGroup / category information
USEPA Category: Aldehydes;Neutral Organics

35

Test Materials
TEST_MATERIAL_INFORMATION: 4-chlorobenzaldehyde
UUID: 6f79d44d-3e27-35b9-9b7c-eae8986a812e
Dossier UUID:
Author:Date: 2022-12-12T13:17:01.188+09:00
Remarks:
Name
4-chlorobenzaldehyde

Composition
Composition
Type
Constituent
Reference substance
4-chlorobenzaldehyde / 4-chlorobenzaldehyde / 104-88-1 / 203-247-4
EC number

EC name203-247-4

EC Inventory

CAS number

CAS name

104-88-1
IUPAC name4-chlorobenzaldehyde

36Literatures
LITERATURE: A reproduction/developmental
toxicity screening test in rats treated orally with 4chlorobenzaldehyde
UUID: 22272062-d1a6-3a5d-b062-26dd76552a05
Dossier UUID:
Author:Date: 2022-12-12T13:41:51.314+09:00
Remarks:

General information
Reference Typestudy report
Title
A reproduction/developmental toxicity screening test in rats treated orally with 4-chlorobenzaldehyde
Author
MHLW, Japan
Year
2012
Bibliographic source
available in the web of Japan Existing Chemical Data Base (JECDB) at http://dra4.nihs.go.jp/
mhlw_data/jsp/SearchPageENG.jsp
Testing facility
BoZo Research Center37

LITERATURE: In Vitro Chromosomal Aberration Test of 4chlorobenzaldehyde on Cultured Chinese Hamster Cells.
UUID: 6b56bfc3-62e7-3148-942a-7fe72e1f0f90
Dossier UUID:
Author:Date: 2017-01-17T12:09:01.000+09:00
Remarks:

General information
Reference Typestudy report
Title
In Vitro Chromosomal Aberration Test of 4-chlorobenzaldehyde on Cultured Chinese Hamster Cells.
Author
MHLW, Japan
Year
2011
Bibliographic source
Japan Existing Chemical Data Base (JECDB)
Testing facility
Safety Research Institute for Chemical Compounds Co., Ltd.

38

LITERATURE: Reverse Mutation Test of 4chlorobenzaldehyde on Bacteria.
UUID: 73ff8829-35c8-3d27-9841-753cf862a37e
Dossier UUID:
Author:Date: 2017-01-17T12:03:06.000+09:00
Remarks:

General information
Reference Typestudy report
Title
Reverse Mutation Test of 4-chlorobenzaldehyde on Bacteria.
Author
MHLW, Japan
Year
2012
Bibliographic source
Japan Existing Chemical Data Base (JECDB)
Testing facility
Safety Research Institute for Chemical Compounds Co., Ltd.

39

LITERATURE: Twenty-eight-day Repeat Dose Oral Toxicity
Test of 4-Chlorobenzaldehyde in RatsUUID: a17c23ea-ac60-3e55-a207-d084befee301
Dossier UUID:
Author:Date: 2017-01-17T11:42:25.000+09:00
Remarks:

General information
Reference Typepublication
Title
Twenty-eight-day Repeat Dose Oral Toxicity Test of 4-Chlorobenzaldehyde in Rats
Author
MHLW
Year
2011
Bibliographic source
available in the web of Japan Existing Chemical Data Base (JECDB) at http://dra4.nihs.go.jp/
mhlw_data/jsp/SearchPageENG.jsp
Testing facility
Safety Research Institute for Chemical Compounds Co., Ltd.

40

Legal Entities
LEGAL_ENTITY: National Institute of Health Sciences
UUID: IUC4-b036ff75-0f3c-323b-b200-ed5f46cf5101
Dossier UUID:
Author:Date: 2022-11-07T15:49:29.000+09:00
Remarks:

General information
Legal entity nameNational Institute of Health Sciences
Remarks
Disclaimer: The contents in this document were created based on the MHLW (Ministry of Health,Labour and Welfare) peer reviewed study reports (in Japanese) in JECDB (Japan Existing Chemical
Database) at http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp. Authorship is in the Divisionof Risk Assessment, the National Institute of Health Sciences, and the contents do not reflect any official MHLW opinions or any other regulatory policies.

Address
Address 1
Tonomachi 3-25-26
Address 2
Kawasaki-ku
Postal code
210-9501
Town
KawasakiRegion / State
Kanagawa
CountryJapan
JP

Identifiers
Other IT system identifiers
IT system
LEO
ID
10767
IT systemIUCLID441

ID
16558402024DIV750

42